After more than a year of searching and planning, Seraxis found a new home in Montgomery County. With the assistance of experienced life sciences logistics company BaneBio, Seraxis was able to seamlessly move into its new facility earlier this year without interrupting its plans to scale and guide its lead cell therapy into the clinic.

Following the close of a $40 million Series C financing round in 2021, Carole Welsch, Chief Business Officer of Seraxis, said the company knew finding a new location was necessary if the diabetes-focused company wanted to grow and scale. In March of that year, months after the financial raise was announced, Seraxis began to search for the new space. Welsch said the search took some time, particularly given the ongoing COVID-19 pandemic and the limited availability of space. After a few months of service, Seraxis found the ideal location in a new facility in Montgomery County, which is where the company wanted to remain after launching in 2013 with its Series A financing. The new space would triple the company’s existing space in the Germantown Innovation Center (GIC) at Pinkney Innovation Complex for Science & Technology at Montgomery College (PIC MC).

Seraxis is a cell therapy company focused on developing cell replacement therapy for insulin-dependent diabetes patients. The company’s lead asset is SR-01, which is being developed to eliminate the need for type 1 diabetes patients to inject insulin. The Seraxis approach to diabetes treatment seeks to replace damaged or lost insulin-producing pancreatic cells with those grown in the Seraxis labs. Those cells were developed with the company’s proprietary human stem cell line, SR1423. Welsch said the company is “racing to the clinic” with SR-01. Seraxis is currently preparing an Investigational New Drug Application for SR-01. She said that is expected to be submitted in early 2023 and, if all goes well, SR-01 could begin Phase I testing in the middle of the year. Read more here.